DHA联合卡维地洛预防多柔比星心脏毒性试验方案
CarDHA试验为一项先导性、随机双盲对照试验,计划纳入32例接受蒽环类治疗的乳腺癌患者,评估DHA联合卡维地洛相较双安慰剂对亚临床心脏毒性的影响。共同主要终点包括心脏磁共振测定的LVEF变化、超声测定的GLS变化、血清hs-cTnT和NT-ProBNP升高及QTc间期。研究假设联合干预组亚临床心脏毒性表现少于安慰剂组,入组与随访正在进行。
要点
- DHA联合卡维地洛可能减少蒽环类治疗的亚临床心脏毒性表现
- 共同主要终点涵盖CMR测LVEF、超声测GLS、血清标志物及QTc间期
- 该先导试验计划入组32例乳腺癌患者,结果尚待报告
核心结论
- 研究假设乳腺癌患者在接受卡维地洛及基于DHA的非缺氧性心肌预处理后,亚临床心脏毒性表现将少于双安慰剂组。
研究设计与样本
- 先导性、随机对照、双盲、两臂临床试验,计划纳入32例接受蒽环类治疗的乳腺癌患者。
- 试验注册于ISRCTN registry,ID为ISRCTN69560410,注册日期2016年6月8日。
主要发现
- 入组和临床结局随访正在进行中,原文未报告结果数据。
关键数值与推荐
- 共同主要终点包括心脏磁共振测定的左心室射血分数(LVEF)变化。
- 共同主要终点包括二维超声心动图测定的整体纵向应变(GLS)变化。
- 共同主要终点包括血清生物标志物hs-cTnT和NT-ProBNP升高。
- 共同主要终点包括一项心电图变量QTc间期。
- 次要终点包括其他影像学、生物标志物及随访期间主要不良心脏事件的发生。
临床怎么用
- 该方案为蒽环类心脏毒性预防提供了联合抗氧化干预的临床试验框架,尚不能据此改变临床实践。
局限性
- 原文未报告研究结果,无法评估干预效果。
- 先导性试验计划样本量仅32例,统计效能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anthracycline-induced cardiotoxicity (AIC), a condition associated with multiple mechanisms of damage, including oxidative stress, has been associated with poor clinical outcomes. Carvedilol, a β-blocker with unique antioxidant properties, emerged as a strategy to prevent AIC, but recent trials question its effectiveness. Some evidence suggests that the antioxidant, not the β-blocker effect, could prevent related cardiotoxicity. However, carvedilol's antioxidant effects are probably not enough to prevent cardiotoxicity manifestations in certain cases. We hypothesize that breast cancer patients taking carvedilol as well as a non-hypoxic myocardial preconditioning based on docosahexaenoic acid (DHA), an enhancer of cardiac endogenous antioxidant capacity, will develop less subclinical cardiotoxicity manifestations than patients randomized to double placebo. METHODS/DESIGN: We designed a pilot, randomized controlled, two-arm clinical trial with 32 patients to evaluate the effects of non-hypoxic cardiac preconditioning (DHA) plus carvedilol on subclinical cardiotoxicity in breast cancer patients undergoing anthracycline treatment. The trial includes four co-primary endpoints: changes in left ventricular ejection fraction (LVEF) determined by cardiac magnetic resonance (CMR); changes in global longitudinal strain (GLS) determined by two-dimensional echocardiography (ECHO); elevation in serum biomarkers (hs-cTnT and NT-ProBNP); and one electrocardiographic variable (QTc interval). Secondary endpoints include other imaging, biomarkers and the occurrence of major adverse cardiac events during follow-up. The enrollment and follow-up for clinical outcomes is ongoing. DISCUSSION: We expect a group of anthracycline-treated breast cancer patients exposed to carvedilol and non-hypoxic myocardial preconditioning with DHA to show less subclinical cardiotoxicity manifestations than a comparable group exposed to placebo. TRIAL REGISTRATION: ISRCTN registry, ID: ISRCTN69560410. Registered on 8 June 2016.
引用
- Carrasco R, Ramirez MC, Nes K, et al. Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled trial (CarDHA trial). Trials. 2020. PMID: 32019575. doi:10.1186/s13063-019-3963-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。